MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.2

Max

1.2

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+289.92% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-2.3M 123M
Eelmine avamishind	1.2
Eelmine sulgemishind	1.2

Uudiste sentiment

By Acuity

60%

40%

293 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. jaan 2026, 16:17 UTC

Omandamised, ülevõtmised, äriostud

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19. jaan 2026, 23:50 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19. jaan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

19. jaan 2026, 22:29 UTC

Market Talk

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19. jaan 2026, 22:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

19. jaan 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

19. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. jaan 2026, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. jaan 2026, 17:09 UTC

Market Talk

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19. jaan 2026, 16:18 UTC

Market Talk

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19. jaan 2026, 16:12 UTC

Market Talk

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19. jaan 2026, 16:06 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19. jaan 2026, 16:04 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19. jaan 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

LVMH, CTG Duty-Free Also Entered Into a MoU

19. jaan 2026, 16:02 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Subscription to Be Made Upon Completion of Transaction

19. jaan 2026, 16:00 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19. jaan 2026, 16:00 UTC

Market Talk

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19. jaan 2026, 15:58 UTC

Omandamised, ülevõtmised, äriostud

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19. jaan 2026, 15:57 UTC

Omandamised, ülevõtmised, äriostud

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19. jaan 2026, 15:57 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Proceeds of Transaction Will Be Paid in Cash

19. jaan 2026, 15:56 UTC

Omandamised, ülevõtmised, äriostud

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19. jaan 2026, 15:53 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19. jaan 2026, 15:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19. jaan 2026, 15:51 UTC

Omandamised, ülevõtmised, äriostud

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19. jaan 2026, 15:39 UTC

Market Talk

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19. jaan 2026, 15:37 UTC

Market Talk

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

289.92% tõus

12 kuu keskmine prognoos

Keskmine 4.64 USD 289.92%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

293 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.